Clinical trials
Diffuse Large B Cell Lymphoma clinical trials
Below are recruiting diffuse large b cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 381 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06550141RecruitingPhase 2
Preventing side effects of CAR-T therapy for large B-cell lymphoma
This trial tests if the drug emapalumab can help prevent toxic side effects often caused by CAR-T cell therapy. It is for adults with certain types of large B-cell lymphoma that have not responded to or returned after initial treatment.
Boston, MassachusettsAges 18 years+ - NCT06554600RecruitingPhase 2
Study of zanubrutinib plus polatuzumab, bendamustine, and rituximab for relapsed DLBCL
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hanzhou, ZhejiangAges 18–75 - NCT06566586RecruitingPhase 2
Study of TQB3702 plus immunochemotherapy for B-cell lymphoma
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06588205Recruiting
Understanding MYC changes in aggressive B-cell lymphomas
This study looks at how changes in the MYC gene affect the outlook for people with certain fast-growing lymphomas, including diffuse large B-cell lymphoma and high-grade B-cell lymphoma. It aims to better understand the tumor environment and how these patients respond to standard chemotherapy.
AlessandriaAges 18–79 - NCT06589089RecruitingPhase 2
Stem cell boost after CAR-T for lymphoma
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
ShanghaiAges 18 years+ - NCT06594640RecruitingPhase 1/Phase 2
R-CMOP for newly diagnosed diffuse large B-cell lymphoma
This trial tests a new combination of drugs (R-CMOP) for people who have just been diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) and have not yet received any treatment for it. The goal is to see if this treatment works well and is safe.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06789159RecruitingPhase 1
VK-2019 for relapsed/refractory EBV-positive DLBCL
This trial tests a new drug called VK-2019 for people whose EBV-positive diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this drug can shrink tumors and help control the cancer.
Lexington, KentuckyAges 18 years+ - NCT06625203Recruiting
Building a large cancer data collection from patients worldwide
This study is building a large collection of cancer data (like medical records, images, and genetic information) from many patients. It aims to learn more about different cancers and may lead to better treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06647940RecruitingPhase 2
Orelabrutinib plus R-CHOP for CD5-positive DLBCL
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
Guangzhou, ChinaAges 18 years+ - NCT06651853RecruitingPhase 2
Radiation therapy with lenalidomide and glofitamab for DLBCL
This trial tests a combination of radiation therapy, lenalidomide, and glofitamab for people with a type of lymphoma called DLBCL that has not responded to or has returned after initial treatment. The goal is to see if this combination can help when other treatments have failed.
Xiamen, FujianAges 18 years+ - NCT06664411RecruitingPhase 2
Pola-ZR2P for untreated DLBCL
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06682130RecruitingPhase 2
Glofitamab before stem cell transplant for relapsed DLBCL
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
Suzhou, JiangsuAges 18–70 - NCT06687772RecruitingPhase 2
Preventing brain relapse in high-risk lymphoma with stem cell transplant
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
St Louis, MissouriAges 18–75 - NCT06693830Recruiting
Blood test guided treatment for newly diagnosed DLBCL
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
New York, New YorkAges 18 years+ - NCT06693973RecruitingEarly Phase 1
AcNK-Sup003 cell therapy for relapsed B-cell lymphoma
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
Wuhan, HubeiAges 18 years+ - NCT06703892RecruitingPhase 1
CAR T-cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
TaipeiAges 18–70 - NCT06707259RecruitingPhase 1
Cord blood CAR NK cells for B-cell lymphoma
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT03501576Recruiting
Testing a flu or COVID vaccine response in people with lymphoma
This study checks how your immune system responds after getting a vaccine. It focuses on people with different types of lymphoma, aiming to learn which immune responses can be measured and whether the vaccines are safe for you.
Atlanta, GeorgiaAges 18 years+ - NCT06249191RecruitingPhase 1/Phase 2
Mosunetuzumab plus chemo for untreated high-grade B-cell lymphoma
This trial tests adding a drug called mosunetuzumab to standard chemotherapy for people with certain aggressive B-cell lymphomas. It aims to see if the combination works better than chemo alone.
Portland, OregonAges 18–75 - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Glendale, ArizonaAges 18 years+ - NCT06716164RecruitingEarly Phase 1
Experimental car-t cell therapy for relapsed b-cell lymphoma
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hangzhou, ZhejiangAges 19–70 - NCT06736613RecruitingPhase 2
Blood test for tumor DNA in high-risk B-cell lymphoma
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
Basking Ridge, New JerseyAges 18 years+ - NCT06755775Recruiting
PET scan to predict immunotherapy success in DLBCL
This trial uses a special PET scan to see if a protein called Granzyme B can predict how well immunotherapy will work for people with DLBCL. It aims to help doctors know earlier if treatment is effective.
ShanghaiAges 18 years+ - NCT06758037RecruitingPhase 2
HiR Plus X therapy for elderly DLBCL patients who can't have chemo
This study tests a new treatment called HiR+X for older adults with a type of lymphoma (DLBCL) who cannot tolerate standard chemotherapy. It aims to offer a gentler but effective option.
Ningbo, ZhejiangAges 70–100
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diffuse large b cell lymphoma?
- Yes. Clin2 currently lists 381 recruiting diffuse large b cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse large b cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse large b cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Large B-cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.